Trademark: 97661691
Word
MTYKA
Status Date
Tuesday, August 20, 2024
Filing Date
Thursday, November 3, 2022
Published for Opposition
Tuesday, January 9, 2024
5 Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors
42 Research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Nov 7, 2022
New Application Entered
Nov 22, 2022
New Application Office Supplied Data Entered
Jun 8, 2023
Assigned To Examiner
Jun 9, 2023
Non-Final Action Written
Jun 9, 2023
Non-Final Action E-Mailed
Jun 9, 2023
Notification Of Non-Final Action E-Mailed
Sep 7, 2023
Application Extension To Response Period - Received
Sep 7, 2023
Application Extension Granted/Receipt Provided
Nov 30, 2023
Teas Response To Office Action Received
Nov 30, 2023
Correspondence Received In Law Office
Dec 1, 2023
Teas/Email Correspondence Entered
Jan 9, 2024
Published For Opposition
Mar 5, 2024
Noa E-Mailed - Sou Required From Applicant
Dec 4, 2023
Approved For Pub - Principal Register
Dec 20, 2023
Notification Of Notice Of Publication E-Mailed
Jan 9, 2024
Official Gazette Publication Confirmation E-Mailed
Jun 27, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 27, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 20, 2024
Sou Teas Extension Received
Aug 20, 2024
Notice Of Approval Of Extension Request E-Mailed
Aug 20, 2024
Sou Extension 1 Filed
Aug 20, 2024
Sou Extension 1 Granted
Jun 27, 2024
Teas Change Of Correspondence Received
Trademark Alertz updated from USPTO on 2030-01-24
